Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
dementia affects 50 million worldwide
Today there are few treatment options for people suffering from Alzheimer’s Disease and other conditions causing cognitive impairment. Syndesi is seeking to address this unmet need with an approach that is distinct from other therapies in development. Our goal is a treatment that makes a meaningful difference to patients.
SynapTIC DYSFUNCTION is central to dementia
Synaptic dysfunction and loss, with the consequent disruption of connectivity between brain regions, underlies the cognitive and psychiatric symptoms of Alzheimer’s and other dementias. The density of SV2A protein, as a marker of synaptic loss, is now being used as an indicator of disease progression. Building on the scientific foundation developed at UCB, Syndesi is developing a novel approach to treat dementia by regulating SV2A function in a unique way.
Our Investors and Partners
Syndesi Therapeutics benefits from the expertise and networks of our investors and partners in Belgium and abroad.